New drug duo shows promise in tough lung cancer
NCT ID NCT02523469
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested a combination of two drugs—nivolumab (Opdivo) and ALT-803—in 67 people with advanced non-small cell lung cancer that had not responded to prior treatments. The goal was to find a safe dose and see if the combination could shrink tumors. The trial is now complete, and results will help guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab (Opdivo) and ALT-803 (an immune-boosting protein)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced lung cancer who have not responded to other therapies.
What could go wrong
This is an early-phase trial with only 67 participants, so results may not apply to everyone. The combination may cause significant side effects or fail to improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Cleveland Clinic Florida
Weston, Florida, 33331, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States